Is Illumina Still a Buy Without the GRAIL Acquisition?

Much to management's chagrin, the giant of gene sequencing hardware, Illumina (NASDAQ: ILMN), recently got a sharp rebuke in the form of an administrative complaint and federal lawsuit from the Federal Trade Commission (FTC) regarding its intended acquisition of GRAIL, a cancer screening company. Is Illumina going to be in trouble if the acquisition falls through?